Summary

Overview
The global integrated organ support therapies market reached US$ 3.91 billion in 2023 and is expected to reach US$ 5.96 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.
Integrated organ support therapies are a multidisciplinary and coordinated set of medical interventions and devices that are designed to sustain, support or temporarily replace the functions of one or multiple failing organs in critically ill patients. These therapies are primarily used in intensive care units and acute care settings where patients suffer from severe health conditions, including multi-organ failure, sepsis, respiratory distress, acute kidney injury or liver failure and among others.
Integrated organ support therapies aim to maintain organ functions to prevent irreversible damage and stabilize patients while underlying causes are treated or the body heals. For instance, according to organdonor.gov, 103,223 men, women and children are on the national transplant waiting list, in such cases, these integrated organ support therapies may be helpful, which further helps to boost the market growth.
Market Dynamics: Drivers
Rising prevalence of chronic and acute organ failures
The increasing prevalence of both chronic and acute organ failures directly correlates with the rising demand for integrated organ support therapies that can manage or replace the function of multiple organs simultaneously, as these conditions significantly increase the need for life-support interventions and multi-organ management. Both chronic and acute organ failures impair the body’s ability to perform essential functions, necessitating integrated organ support devices and therapies that can temporarily replace or support these failing organs.
For instance, according to the study conducted by the National Institute of Health (NIH), the study revealed the incidence of new organ failure at 1,342/1,00,000 person-years and a prevalence of 5.2% of all emergency department contacts. One-year all-cause mortality was 29.8% among organ failure patients. As organ failures are on the rise, the demand for integrated organ support therapies is expected to grow continuously.
Restraints
Factors such as risks and complications associated with organ support therapies and devices, high costs of organ support devices and therapies, complex regulatory approval processes, high maintenance and operational requirements and limited portability and mobility of devices are expected to hamper the integrated organ support therapies market.
While these therapies are essential for managing patients with multi-organ failure, the associated risks, complications and potential side effects can affect their adoption and efficacy. The complexity of using such devices also places an additional burden on healthcare systems, which can hamper the growth of the market.
For instance, one of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, this further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.
Segment Analysis
The global integrated organ support therapies market is segmented based on therapy type, modality, application, patient type, end-user and region.
The multi-organ failure from the application segment accounted for approximately XX% of the global integrated organ support therapies market share
The multi-organ failure segment is expected to hold the largest market share over the forecast period. Integrated organ support therapies are critical in the management of multi-organ failure, a condition where two or more organs fail simultaneously, often resulting from severe infections, trauma or underlying chronic conditions. These therapies provide life-sustaining support to failing organs, enabling doctors to stabilize the patient while the underlying causes are treated or recovery occurs.
For instance, according to a study conducted by ScienceDirect, in surgical critical care units, 50–80% of all deaths are due to multiple organ failure (MOF). The origin of MOF is still not well understood, therapy is still mainly supportive and the death rate (30–70% in most series) has not significantly decreased even though the syndrome was first identified more than 20 years ago. Thus, the rising burden of MOF further increases the demand for integrated organ support therapies.
Geographical Analysis
North America accounted for approximately XX% of the global integrated organ support therapies market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases and critical illnesses and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.
For instance, according to the American Kidney Fund Organization, about 808,000 Americans are living with kidney failure. According to the CDC, the US Department of Health and Human Services estimated that 129 million Americans suffer from at least one severe chronic disease.
The U.S. healthcare system is the largest spender on healthcare globally. For instance, according to the U.S. Centers for Medicare & Medicaid Services, US healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. As a share of the nation's GDP, health spending accounted for 17.3%, which includes significant expenditures on critical care technologies, including ECMO, CRRT and others.
Market Segmentation
By Therapy Type
• Extracorporeal Membrane Oxygenation (ECMO)
o Veno-Venous (VV)
o Veno-Arterial (VA)
o Arterio-Venous (AV)
• Continuous Renal Replacement Therapy (CRRT)
o Continuous Venovenous Hemofiltration (CVVH)
o Continuous Venovenous Hemodialysis (CVVHD)
o Continuous Venovenous Hemodiafiltration (CVVHDF)
o Slow Continuous Ultrafiltration (SCUF)
• Extracorporeal CO₂ Removal (ECCO₂R)
• Liver Support Systems
o Molecular Adsorbent Recirculating System
o Bioartificial Liver Support
• Cardiac Assist Devices
o Intra-aortic Balloon Pump
o Ventricular Assist Devices
o Total Artificial Organs

By Modality
• Portable/Transportable Devices
• Bedside Devices
• Implantable Devices
By Application
• Respiratory Failure
• Cardiac Failure
• Liver Failure
• Kidney Failure
• Multi-Organ Failure
By Patient Type
• Adult Patients
• Pediatric Patients
• Neonatal Patients
By End-User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Intensive Care Units (ICUs)
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the integrated organ support therapies market include Emulate, Inc., Baxter International Inc., Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, Fisher & Paykel Healthcare Limited and among others.
Key Developments
 In August 2024, Talphera, Inc. declared that the NEPHRO CRRT study's first patient has been recruited. 166 individuals receiving continuous renal replacement therapy (CRRT) at up to 14 clinical locations across the US will be included in the NEPHRO CRRT registrational research. The mean post-filter activated clotting time for circuits injected with nafamostat versus placebo for the first 24 hours is the study's main outcome.
 In April 2022, Baxter International Inc. released the U.S. Food and Drug Administration (FDA) 510(k) clearance 0f ST Set for use in continuous renal replacement therapy (CRRT). The ST Set is a disposable, extracorporeal (outside the body) circuit that comes pre-connected and may be used with the PrisMax or Prismaflex control units (monitors). It purifies blood through a semipermeable membrane.
Why Purchase the Report?
• To visualize the global integrated organ support therapies market segmentation based on therapy type, modality, application, patient type, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the integrated organ support therapies market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global integrated organ support therapies market report would provide approximately 78 tables, 77 figures and 179 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Modality
3.3. Snippet by Application
3.4. Snippet by Patient Type
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Chronic and Acute Organ Failure
4.1.1.2. Technological Advancements in Organ Support Devices
4.1.2. Restraints
4.1.2.1. Risks and Complications Associated with Organ Support Therapies and Devices
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Therapy Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Extracorporeal Membrane Oxygenation (ECMO)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Veno-Venous (VV)
6.2.4. Veno-Arterial (VA)
6.2.5. Arterio-Venous (AV)
6.3. Continuous Renal Replacement Therapy (CRRT)
6.3.1. Continuous Venovenous Hemofiltration (CVVH)
6.3.2. Continuous Venovenous Hemodialysis (CVVHD)
6.3.3. Continuous Venovenous Hemodiafiltration (CVVHDF)
6.3.4. Slow Continuous Ultrafiltration (SCUF)
6.4. Extracorporeal CO₂ Removal (ECCO₂R)
6.5. Liver Support Systems
6.5.1. Molecular Adsorbent Recirculating System
6.5.2. Bioartificial Liver Support
6.6. Cardiac Assist Devices
6.6.1. Intra-aortic Balloon Pump
6.6.2. Ventricular Assist Devices
6.6.3. Total Artificial Organs
7. By Modality
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
7.1.2. Market Attractiveness Index, By Modality
7.2. Portable/Transportable Devices *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bedside Devices
7.4. Implantable Devices
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Respiratory Failure*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiac Failure
8.4. Liver Failure
8.5. Kidney Failure
8.6. Multi-Organ Failure
9. By Patient Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.1.2. Market Attractiveness Index, By Patient Type
9.2. Adult Patients*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pediatric Patients
9.4. Neonatal Patients
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Ambulatory Surgical Centers
10.5. Intensive Care Units (ICUs)
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Emulate, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Baxter International Inc.
13.3. Fresenius Medical Care AG
13.4. Getinge AB
13.5. LivaNova, Inc.
13.6. Asahi Kasei Corporation
13.7. ADVITOS GmbH
13.8. NIHON KOHDEN CORPORATION
13.9. Vapotherm
13.10. Fisher & Paykel Healthcare Limited
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us